Abstract
Objective
Sayana® Press,
1Sayana Press is a registered trademark of Pfizer Inc.
a new subcutaneous formulation and presentation of a popular injectable contraceptive,
has the potential to expand non-clinic access to contraception, including home and
self-injection (HSI). This study collected information from potential users and stakeholders
on their perceptions and preferences, the feasibility of an HSI of Sayana Press program
and key policy considerations.Study design
PATH conducted 62 interviews and 7 focus groups with family planning users, non-users,
physicians, other health care providers and key informants in the Oromia region of
Ethiopia. Participants watched a demonstration and tested the device on a model mid-interview.
The study did not involve product use in humans.
Results
Women found the product easy to use, liked the simple design and valued the time and
expense that could be saved through HSI of Sayana Press (HSI-SP). Of those with inhibitions
about their ability to self-inject, most shifted their opinion favorably after demonstration.
The majority of other stakeholders also supported HSI-SP and thought it could increase
contraceptive use in Ethiopia, and they suggested that any successful program must
include proper training and supervision, particularly regarding product storage and
waste management.
Conclusion
The data provide findings to stimulate further research and support future planning.
They suggest that HSI-SP may meet the needs of many women if key requirements and
challenges are met. It may also be necessary to revise policies and guidelines to
integrate the approach with national family planning strategies.
Implications
This study provides the first available data on perceptions, feasibility and requirements
for HSI of Sayana Press in a low-resource setting. Findings provide insights that
may guide future implementation strategies, strengthen non-clinic family planning
access programs and stimulate continued research.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to ContraceptionAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
United Nations, Department of Economic and Social Affairs, Population Division [Internet]. World Contraception Use 2011. New York: United Nations; 2011. Available from: http://www.un.org/esa/population/publications/contraceptive2011/wallchart_front.pdf.
- Team-based codebook development: structure, process, and agreement.in: Guest G. MacQueen K.M. Handbook for team-based qualitative research. AltaMira Press, Lanham (MD)2008: 119-136
- Self-administration with Uniject of the once-a-month injectable Cyclofem.Contraception. 1997; 56: 301-304
- Self-administration of subcutaneous depot medroxyprogesterone acetate for contraception: feasibility and acceptability.Contraception. 2012; 85: 453-457
- Pilot study of home self-administration of subcutaneous depo-medroxyprogesterone acetate for contraception.Contraception. 2012; 85: 458-464
- Self-administration of subcutaneous depot medroxyprogesterone acetate by adolescent women.Contraception. 2013; 88: 401-407
- Randomized clinical trial of self versus clinical administration of subcutaneous depot medroxyprogesterone acetate.Contraception. 2014; 89: 352-356
- Provider acceptability of Sayana® Press: results from community health workers and clinic-based providers in Uganda and Senegal.Contraception. 2014; 89: 368-373
- Observational study of the acceptability of Sayana® Press among intramuscular DMPA users in Uganda and Senegal.Contraception. 2014; 89: 361-367
Article info
Publication history
Published online: December 30, 2013
Accepted:
December 19,
2013
Received in revised form:
November 19,
2013
Received:
August 30,
2013
Footnotes
☆Funding: This study was implemented by PATH with funding from the Bill & Melinda Gates Foundation, the U.S. Agency for International Development DELIVER PROJECT, Task Order 4 under U.S. Agency for International Development contract no. GPO-I-00-06-00007-00 and PATH individual donor Stephanie Evans. The views expressed herein are solely those of the authors and do not necessarily reflect the views of the donors.
☆☆Conflict of interest: None of the authors has a conflict of interest.
Identification
Copyright
© 2014 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
